top of page

The Inflation Reduction Act: Implications For Biopharma Companies And Patients

See our webinar, featuring DLA Piper, on the Inflation Reduction Act healthcare provisions.

 

Incubate hosted a webinar today featuring Kirsten Axelsen, Senior Health Advisor from DLA Piper, Jim Greenwood, Chair of the Life Sciences Group at DLA Piper, and Geoffrey Levitt, the Co-Chair of the FDA Regulatory Practice at DLA Piper.


The conversation focused on the state of play around drug price controls and Medicare Part D; the key health provisions of the Inflation Reduction Act; downstream implications of the legislation; and then will conclude with a Q&A session.




0 views0 comments

Kommentare


bottom of page